InvestorsHub Logo
Followers 312
Posts 24877
Boards Moderated 9
Alias Born 10/26/2008

Re: Dengxiaoping post# 1807

Wednesday, 09/22/2021 5:48:14 AM

Wednesday, September 22, 2021 5:48:14 AM

Post# of 2147
Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep. 21, 2021 4:19 PM ET Hepion Pharmaceuticals, Inc. (HEPA)


https://seekingalpha.com/article/4456410-additional-phase-iia-data-confirms-hepions-crv431-as-a-very-promising-nash-candidate-drug?mail_subject=francisco-javier-garcia-additional-phase-iia-data-confirms-hepion-s-crv431-as-a-very-promising-nash-candidate-drug&utm_campaign=rta-author-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha

Given the direct relationship that the level of the Pro-C3 biomarker has with liver fibrosis, we are going to compare the behavior of the Pro-C3 biomarker in different trials carried out by companies with candidate drugs for NASH and thus be able to determine if the data provided by Hepion is promising.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News